Kratos Validates Turbomachinery for Lockheed Propulsion, but Cash Conversion Remains the Real Test

What happened

On July 27, 2026, Kratos announced successful delivery and validation of advanced turbomachinery for Lockheed Martin’s next-generation missile propulsion system, a technical milestone that underscores its role as a specialized supplier in the hypersonics and rocket markets. This achievement aligns with Kratos’s strategic big bet on propulsion and test infrastructure, but it does not directly address the company’s pressing financial challenges: negative free cash flow, rising DSO, and elevated working capital highlighted in the latest 10-Q. The news may bolster the narrative of Kratos as a critical defense technology enabler, yet the stock already trades at 70.7x EV/EBITDA, embedding high expectations for execution that have not yet materialized. With the share price at $45.94, near our base-case value of $49, the core investment thesis remains contingent on funded backlog growth and cash conversion over the next two quarters. Until those appear, this component delivery is a positive but insufficient data point to warrant a rating change.

Implication

The turbomachinery delivery confirms Kratos’s engineering capability in propulsion subsystems, but it lacks the scale to shift the financial needle. The investment case still hinges on Q2 and Q3 2026 filings showing funded backlog above $1.55B, DSO declining from 130 days, and operating cash flow turning positive. Absent these, the 265.7x P/E and negative free cash flow guidance of $(85)–$(105)M leave the stock vulnerable. Downside risks include persistent working capital builds and limited Valkyrie production scaling, which could push the stock toward our $36 bear case. We would need clear evidence of customer-funded task orders converting to cash to upgrade the thesis; until then, attractive entry remains near $38.

Thesis delta

The delivery adds incremental technical validation for Kratos’s propulsion business but does not address the central challenges of cash conversion, funded backlog growth, or working capital unwind. The investment thesis remains unchanged: a WAIT rating is appropriate pending observable improvements in financial metrics, not technical milestones alone.